Exabis Library
Welcome to the e-CCO Library!
P630: Inflammatory bowel disease in immigrants to Spain: results of the EIIMIGRA study from GETECCU (ENEIDA registry)
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P630: Systematic review and meta-analysis: Diagnostic delay and the subsequent impact on the disease course of adult Inflammatory Bowel Disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P630: The long-term efficacy of adalimumab on Crohn's disease comorbid with perianal lesions and poor prognostic factor analysis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P630: Upadacitinib Improves Clinical Outcomes in Patients with Moderate to Severely Active Crohn's Disease Irrespective of Previous Failure to Respond to Biologics or Conventional Therapies
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P631 Predictors of vedolizumab treatment persistence in bio-naïve ulcerative colitis patients
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P631: Development and validation of a clinical scoring tool for predicting treatment outcomes with vedolizumab in patients with ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P631: Food triggers in inflammatory bowel disease from the patients’ and doctors’ perspective
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P631: Impact of Covid-19 pandemic on initiation of immunosuppressive treatment in immune-mediated diseases. -A nationwide, retrospective study-
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P631: Long-term safety of vedolizumab versus other biologic agents in ulcerative colitis (UC) and Crohn's Disease (CD): Results from a large multinational prospective observational study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P631: Results and predictors of outcome of endoscopic balloon dilation of colonic strictures in inflammatory bowel diseases
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P631: Treatment of established post-operative recurrence of Crohn’s disease with anti-TNF agents: Preliminary data of a multicentre, nationwide study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P632 Vedolizumab dose escalation in patients with inflammatory bowel disease experiencing loss of response: A systematic review and meta-analysis of real-world evidence
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P632: Allogenic hPDMSCs gelatum in the treatment of perianal fistulas in patients with Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P632: Comparative analysis of the pharmacokinetics of Inflectra® biosimilar with Remicade® in the induction phase of remission in patients with Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P632: Estimating indirect and out-of-pocket disease-associated costs in paediatric Inflammatory Bowel Disease: a nation-wide cross-sectional analysis
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P632: Etrasimod induction therapy in moderately to severely active Crohn's disease: results from a phase 2, randomised, double-blind substudy
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P632: Is the gender or age of the physician key to a good physician-patient with Inflammatory Bowel Disease relationship?
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P632: Trough levels of golimumab at Week 6 predict drug retention rate in ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P633 Sustained reduction of IL-23-related cytokines IL-17A and IL-22 in a phase 2 study of mirikizumab in the treatment of patients with moderately-to-severely active ulcerative colitis through week 52
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM